This pilot clinical trial studies if cells donated by a close genetic relative can help
maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive
a standard induction chemotherapy. If a complete remission results they will receive
irradiated allogeneic cells from a HLA haploidentical relative. Only patients who obtain a CR
after the standard induction chemotherapy are eligible for the experimental therapy
(irradiated haploidentical cells).
Phase:
N/A
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey